A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Phase 2

Pfizer

Salmeterol Xinafoate